| Chelsie Lynn Getzlaff, MS | |
|
12700 11th Ave Sw, Burlington, ND 58722-9510 | |
| (701) 720-5381 | |
| Not Available |
| Full Name | Chelsie Lynn Getzlaff |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 12700 11th Ave Sw, Burlington, North Dakota |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023560448 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Chelsie Lynn Getzlaff, MS 12700 11th Ave Sw, Burlington, ND 58722-9510 Ph: (701) 720-5381 | Chelsie Lynn Getzlaff, MS 12700 11th Ave Sw, Burlington, ND 58722-9510 Ph: (701) 720-5381 |
News Archive
OPKO Health, Inc. has entered into a definitive agreement to acquire Inspiro Medical Ltd., an Israeli medical device company developing a new platform to deliver small molecule drugs such as corticosteroids and beta agonists or larger molecules to treat respiratory diseases. Inspiro's Inspiromatic is a "smart" easy-to-use dry powder inhaler with several advantages over existing devices.
Specialty drug discovery company, Innovimmune Biotherapeutics, Inc. has been awarded a $600,000 Advanced Technology Small Business Innovation Research Grant from the National Institutes of Health (NIH).
Shionogi Inc., a U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. Food and Drug Administration approval of CUVPOSA™ (glycopyrrolate), the first liquid treatment for patients ages 3-16 who suffer from chronic severe drooling associated with neurologic conditions such as cerebral palsy. CUVPOSA™ was designated an Orphan Drug by the FDA.
Currently, large doses of chemotherapy are required when treating certain forms of cancer, resulting in toxic side effects. The chemicals enter the body and work to destroy or shrink the tumor, but also harm vital organs and drastically affect bodily functions. Now, scientists at the University of Missouri have proven that a new form of prostate cancer treatment that uses radioactive gold nanoparticles, and was developed at MU, is safe to use in dogs.
› Verified 3 days ago
Mrs. Mandy Dawn Lemer, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 301 Wallace Street, Burlington, ND 58722 Phone: 701-839-7135 |